RecruitingPHASE1, PHASE2NCT04742634

Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant

Studying C syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Washington University School of Medicine
Principal Investigator
Meagan Jacoby, M.D., Ph.D.
Washington University School of Medicine
Intervention
DEC-C(drug)
Enrollment
209 enrolled
Eligibility
18-75 years · All sexes
Timeline
20222033

Study locations (1)

Collaborators

Taiho Oncology, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04742634 on ClinicalTrials.gov

Other trials for C syndrome

Additional recruiting or active studies for the same condition.

See all trials for C syndrome

← Back to all trials